Test Price
2,800 AED✅ Home Collection Available
ADA2 Gene Sequencing for Childhood-Onset Polyarteritis Nodosa | 2800 AED | 2026 DHA Guidelines
تحليل جين ADA2 لالتهاب الشرايين العقدي الطفولي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM‑11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA‑licensed experts.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
الملخص التنفيذي: يوفر هذا الاختبار الجيني المتطور باستخدام تقنية التسلسل الجيني (NGS) تشخيصًا دقيقًا لحالة التهاب الشرايين العقدي الطفولي المرتبط بجين ADA2، بدقة تصل إلى 99.9% وفقًا لإرشادات هيئة الصحة بدبي لعام 2026، مع خدمة سحب منزلي معتمدة واستشارة ما بعد الفحص.
Overview
The ADA2 Gene Sequencing for Childhood-Onset Polyarteritis Nodosa is a comprehensive Next‑Generation Sequencing (Genetic Test replaces clinical suspicion with molecular certainty, enabling early targeted therapy and family screening.
| Feature | Our ADA2 Genetic Test | Closest Alternative (Imaging/Clinical Criteria) |
|---|---|---|
| Diagnostic Precision | 99.9% mutation detection | Anatomic suspicion; no molecular confirmation |
| Methodology | NGS (Next‑Generation Sequencing) – full gene coverage | Doppler ultrasound, angiography, biopsy |
| Turnaround Time | 3 to 4 Weeks | Variable; often delayed by specialist referral |
| Clinical Actionability | Immediate genetic counselling & targeted therapy (e.g., anti‑TNF) | Empiric immunosuppression without genetic guidance |
Physician Insight & Safety Protocol
“As a DHA‑licensed practitioner, I emphasize that this genetic test is a cornerstone in diagnosing deficiency of adenosine deaminase 2 (DADA2), yet it must be correlated with clinical phenotype, inflammatory markers, and family history. A negative result does not exclude all vasculitides, and a positive finding guides life‑saving, personalised therapy but requires interdisciplinary follow‑up.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠️ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Abrupt cessation of immunosuppressants, corticosteroids, or antihypertensives can precipitate a life‑threatening vasculitic flare.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active severe infection (e.g., sepsis, meningitis), inability to obtain an adequate blood sample, or patient refusal.
- Red Flags – Seek Emergency Care Immediately: Sudden high fever >39 °C, acute severe abdominal pain, new neurological deficits (focal weakness, confusion), or rapidly progressive skin necrosis. These may indicate an acute vasculitis crisis.
- Inform the phlebotomist of any bleeding disorder or anticoagulant use before the home collection.
Patient FAQ & Clinical Guidance
1. What exactly is the ADA2 gene test and how is it performed?
The ADA2 gene test is a blood‑based Next‑Generation Sequencing analysis that reads the entire coding region of the ADA2 gene to identify mutations causing childhood‑onset polyarteritis nodosa (DADA2). After a simple venous blood draw (or home collection), DNA is extracted and sequenced; results are returned in 3‑4 weeks with a comprehensive clinical interpretation.
ما هو اختبار جين ADA2؟ هو تحليل للدم بتقنية التسلسل الجيني (NGS) يقرأ كامل الجين المسؤول عن التهاب الشرايين العقدي الطفولي، ويحدد الطفرات المسببة للمرض في غضون 3‑4 أسابيع.
2. Who should consider this test for their child?
Physicians recommend this test for any child presenting with recurrent unexplained fevers, skin nodules or livedo racemosa, early‑onset strokes or hypertension, or a family history of polyarteritis nodosa, because these features strongly suggest DADA2. Genetic counselling is mandatory before testing to assess inheritance and inform the family.
من يجب أن يخضع لهذا الاختبار؟ أي طفل يعاني من حمى متكررة غير مبررة أو عقيدات جلدية أو سكتات دماغية مبكرة، خاصة مع تاريخ عائلي للمرض، بعد جلسة استشارة وراثية.
3. How does this affect management and insurance coverage in the UAE?
A positive result triggers immediate initiation of anti‑TNF therapy (often covered under UAE federal genetic disorder programmes), while negative findings redirect the diagnostic work‑up; our team provides direct insurance verification via WhatsApp and ensures compliance with Federal Decree‑Law No. 41 of 2024 on genetic data privacy.
كيف يؤثر ذلك على العلاج والتأمين؟ النتيجة الإيجابية تستوجب البدء الفوري بعلاج مثبطات عامل نخر الورم، وتوفر خدمتنا التحقق المباشر من التغطية التأمينية مع الالتزام بقانون البيانات الجينية الاتحادي رقم 41 لعام 2024.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians